Vascular Pharma has entered into a definitive M&A agreement with Janssen Biotech which grants Janssen the exclusive right, at Janssen’s discretion, to acquire Vascular Pharma following the completion of a planned Phase 2 clinical study of VPI-2690B upon pre-negotiated terms and conditions set forth in the agreement.
Janssen will provide Vascular Pharma with an initial upfront payment and certain contingent milestone payments in return for its rights under this M&A agreement.
Vascular Pharma’s development efforts are focused on its preclinical candidate, VPI-2690B, which targets a pathway that is stimulated by hyperglycemia.
For further deal information visit Current Agreements (subscription required)
Read: more on M&A deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Merger and Acquisition Terms and Agreements
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity